Ocumension Therapeutics Receives NMPA Approval to Market OT-702 in China
Ocumension Therapeutics has received approval from China's NMPA to market OT-702, an EYLEA® biosimilar, for treating neovascular age-related macular degeneration and diabetic macular edema in adults. Developed with Shandong Boan Biotechnology, Ocumension holds exclusive rights for its promotion and commercialization in China.
Ocumension Therapeutics has received approval from the National Medical Products Administration (NMPA) of China to market OT-702 (Aflibercept Intravitreous Injection, an EYLEA® biosimilar) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults. OT-702 was developed in partnership with Shandong Boan Biotechnology Co., Ltd. (Boan Bio), and Ocumension holds the exclusive promotion and commercialization rights for the product in China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251126-11928891), on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
